Phase I/IIa Study: RR001 Administered Following Chemotherapy Cycles for Patients With Locally Advanced Pancreatic Carcinoma

Inclusion Criteria:

• Patients with confirmed pancreatic ductal adenocarcinoma classified as locallyadvanced pancreatic adenocarcinoma (LPAC)

• Patients with no evidence of peritoneal or hematogenous metastasis

• Patients classified as non-resectable locally advanced pancreatic carcinoma (LAPC)based on imaging (TC and NMR), on multidisciplinary staff evaluation by at least anoncologist, radiologist and a qualified digestive surgeon and accounting forAJCC/UICC TNM and clinical staging

• Measurable tumor according RECIST criteria v 1.1

• Low tumor burden with at least one lesion equal/less than 3,5 cm that is suitablefor US guided injection (and needle biopsy).

• Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2

• Patients must be eligible for chemotherapy treatment (based on standard of care)treatment

• Patient older than 18 years of age

• Adequate hepatic and kidney function/Safe hematologic profile

• Negative serum pregnancy test for females of childbearing potential

• Willingness and ability to comply with the scheduled visits, treatment plan, imagingprocedures, laboratory tests and other study procedures, including lipoaspiratecollection (liposuction)

Exclusion Criteria:

• Patient with pancreatic cystic tumor or pancreatic pseudocyst

• Patient with pancreatic tumor different from adenocarcinoma (endocrine, metastases)

• Patients with unknown stage or recurrent pancreatic cancer

• Patients with immunosuppression or susceptibility to viral infection

• Patients with HIV, hepatitis B, hepatitis C, HTLV-I/II, Treponema Palliduminfections

• Patients with liver cirrhosis or other documented liver diseases

• Patient contraindication to use chemotherapy treatments

• Previous of radiotherapy and chemotherapy for PDAC

• Previous hematopoietic stem cell or organ transplantation

• Irreversible cardiac arrhythmias requiring permanent medication

• Heart insufficiency (> grade II, New York Heart Association NYHA criteria)

• History within the last year of acute or subacute coronary syndromes includingmyocardial infarction, unstable or severe stable angina pectoris

• Uncontrolled hypertension

• Other malignancies within the past 2 years (not including basal cell carcinoma ofthe skin, prostate cancer or in situ cervix carcinoma, in situ melanoma).

• Active autoimmune disease

• Use of any investigational agents within 21 days from the administration of studytreatment

• Patient has had major open surgery prior to the administration of study treatment

• Uncontrolled intercurrent illness including but not limited to psychiatricillness/social situations that in the opinion of the Investigator would compromisecompliance of study requirements or put the patient at unacceptable risk